Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study (NCT02181413) demonstrated improved progression-free survival with ixazomib maintenance versus placebo post autologous stem cell transplant (ASCT) in multiple myeloma patients. We report additional safety data from TOURMALINE-MM3 to...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Ann Hematol
Autores principales: Kaiser, Martin, Beksaç, Meral, Gulbrandsen, Nina, Schjesvold, Fredrik, Hájek, Roman, Moreau, Philippe, de Arriba de la Fuente, Felipe, Mateos, María-Victoria, West, Sharon, Spencer, Andrew, Rajkumar, S. Vincent, Suryanarayan, Kaveri, Czorniak, Michael, Li, Cong, Teng, Zhaoyang, Labotka, Richard, Dimopoulos, Meletios A.
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7340660/
https://ncbi.nlm.nih.gov/pubmed/32613281
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-020-04149-5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares